Indoco Remedies sterile manufacturing plant in Goa gets 2 observations from UK-MHRA

'The successful closure of the MHRA inspection is encouraging and reflects the immense learning and adaption by our technical team. The Sterile manufacturing site is expected to receive the EUGMP certification soon, following this recent inspection, " Indoco Remedies said in a filing.

Mumbai: Indoco Remedies recently announced that it's sterile manufacturing facility (Plant II) at Verna, Goa, has successfully concluded an inspection conducted by the UK Health Regulator, MHRA.

The inspection was held from 16th to 20th September 2019 and resulted in 2 observations.

Commenting on this positive development, Ms Aditi Kare Panandikar, Managing Director -Indoco Remedies Ltd. said, 'The successful closure of the MHRA inspection is encouraging and reflects the immense learning and adaption by our technical team. The Sterile manufacturing site is expected to receive the EUGMP certification soon, following this recent inspection."

Read Also: UK drug regulator MHRA reinstates full GMP status to Indoco Goa Plant I

Headquartered in Mumbai, Indoco has 9 manufacturing facilities, 6 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by USFDA, UK MHRA, TGA-Australia, MCC-South Africa, etc.

Indoco has a brand portfolio in various therapeutic segments including Respiratory, Anti-Infective, Dental Care, Pain Management, Gastro-intestinal, Ophthalmic, Cardiovascular, Anti-Diabetics, Anti-Obesity, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Oxipod, Cital, ATM, Cloben-G, Sensoform, Sensodent-KF, Karvol Plus, Glychek, Kidodent, Carmicide, Bactogard, etc. On the international front, Indoco has tie-ups with large generic companies like Watson (Actavis)- the USA and ASPEN-South Africa.

Read Also: Indoco Remedies successfully completes USFDA inspection of CRO Anacipher in Hyderabad